​

Passage Bio (PASG) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

PASG Stock Forecast

Passage Bio (PASG) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $10.00, with a high of $15.00 and a low of $7.00. This represents a 71.23% increase from the last price of $5.84.

- $3 $6 $9 $12 $15 High: $15 Avg: $10 Low: $7 Last Closed Price: $5.84

PASG Stock Rating

Passage Bio stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (54.55%), 5 Hold (45.45%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 5 6 Strong Sell Sell Hold Buy Strong Buy

PASG Price Target Upside V Benchmarks

TypeNameUpside
StockPassage Bio71.23%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts333
Avg Price Target$10.00$10.00$10.00
Last Closing Price$5.84$5.84$5.84
Upside/Downside71.23%71.23%71.23%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26-5---5
Mar, 26-6---6
Feb, 26-6---6
Jan, 26-6---6
Dec, 25-6---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 21, 2026Oppenheimer$15.00$6.08146.71%156.85%
Apr 21, 2026Wedbush$8.00$6.2528.00%36.99%
Apr 21, 2026Janani SundararajanChardan Capital$7.00$6.2512.00%19.86%
Jan 19, 2022Madhu KumarGoldman Sachs$6.00$4.9421.46%2.74%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 21, 2026Cowen & Co.Holddowngrade
Apr 21, 2026WedbushReduceNeutraldowngrade
Apr 20, 2026WedbushReduceinitialise
May 20, 2025GuggenheimBuyBuyhold
Sep 17, 2024Canaccord GenuityBuyBuyhold
Sep 03, 2024Rodman & RenshawBuyinitialise
Nov 14, 2023Raymond JamesOutperformOutperformhold
Dec 15, 2022Chardan CapitalBuyBuyhold
Nov 11, 2022GuggenheimBuyBuyhold
May 17, 2022Raymond JamesOutperformOutperformhold

Financial Forecast

EPS Forecast

$-40 $-31 $-22 $-13 $-4 $5 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-37.29$-21.44$-14.35---
Avg Forecast$-1.85$-0.99$-0.66$-0.74$-0.19$0.60
High Forecast$-1.66$-0.96$-0.53$-0.28$0.10$0.60
Low Forecast$-1.95$-1.00$-0.84$-1.34$-0.45$0.60
Surprise %1915.68%2065.66%2074.24%---

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$1.90M$2.00M$45.01M$156.77M
High Forecast--$1.90M$2.00M$45.01M$156.77M
Low Forecast--$1.90M$2.00M$45.01M$156.77M
Surprise %------

Net Income Forecast

$-150M $-110M $-70M $-30M $10M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-102.06M$-64.77M$-45.52M---
Avg Forecast$-102.06M$-53.66M$-37.63M$-72.43M$-9.56M$32.66M
High Forecast$-91.14M$-52.37M$-29.03M$-15.23M$5.54M$32.66M
Low Forecast$-106.78M$-54.96M$-46.24M$-73.42M$-24.66M$32.66M
Surprise %-20.69%20.96%---

PASG Forecast FAQ

Is Passage Bio stock a buy?

Passage Bio stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Passage Bio is a favorable investment for most analysts.

What is Passage Bio's price target?

Passage Bio's price target, set by 11 Wall Street analysts, averages $10 over the next 12 months. The price target range spans from $7 at the low end to $15 at the high end, suggesting a potential 71.23% change from the previous closing price of $5.84.

How does Passage Bio stock forecast compare to its benchmarks?

Passage Bio's stock forecast shows a 71.23% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Passage Bio over the past three months?

  • April 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Passage Bio’s EPS forecast?

Passage Bio's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.74, marking a -94.84% decrease from the reported $-14.35 in 2025. Estimates for the following years are $-0.19 in 2027, and $0.6 in 2028.

What is Passage Bio’s revenue forecast?

Passage Bio's average annual revenue forecast for its fiscal year ending in December 2026 is $2M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $45.01M, and $156.77M for 2028.

What is Passage Bio’s net income forecast?

Passage Bio's net income forecast for the fiscal year ending in December 2026 stands at $-72.426M, representing an 59.10% increase from the reported $-45.522M in 2025. Projections indicate $-9.564M in 2027, and $32.66M in 2028.